Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer.

ESMO Gastrointest Oncol · 2024 · PMC12836702 · PMID 41647585

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

showed a trendP = 0.068so close (0.05 < p ≤ 0.1)

By contrast, the intestinal subtype showed a trend toward benefit with an aHR of 0.52 (95% CI 0.26-1.05, P = 0.068) for OS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.